Citation Report
List of articles citing

Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases

DOI: 10.1002/ppul.23133
Pediatric Pulmonology, 2015, 50, 410-9.

Source: https://exaly.com/paper-pdf/62788584/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
38	A disorder of surfactant metabolism without identified genetic mutations. *Italian Journal of Pediatrics*, **2015**, 41, 93	3.2	3
37	Childhood interstitial lung disease: A systematic review. *Pediatric Pulmonology*, **2015**, 50, 1383-92	3.5	36
36	Interstitial Lung Disease in Children Younger Than 2 Years. *Pediatrics*, **2016**, 137,	7.4	32
35	Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate. *Archives of Disease in Childhood*, **2017**, 102, 84-90	2.2	21
34	Hydroxychloroquine retinopathy. *Eye*, **2017**, 31, 828-845	4.4	99
33	Delayed Presentation and Prolonged Survival of a Child with Surfactant Protein B Deficiency. *Journal of Pediatrics*, **2017**, 190, 268-270.e1	3.6	9
32	ATS Core Curriculum 2017: Part II. Pediatric Pulmonary Medicine. *Annals of the American Thoracic Society*, **2017**, 14, S165-S181	4.7	3
31	Genetics and Physiology of Surfactant Protein Deficiencies. **2017**, 843-854.e2		1
30	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. *Respiratory Medicine*, **2018**, 121-161	0.2	2
29	Genetic causes and clinical management of pediatric interstitial lung diseases. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 253-259	3	21
28	Diagnostic accuracy and therapeutic relevance of thoracoscopic lung biopsies in children. *Pediatric Pulmonology*, **2018**, 53, 948-953	3.5	11
27	Lung Diseases Associated With Disruption of Pulmonary Surfactant Homeostasis. **2019**, 836-849.e5		
26	Pulmonary Fibrosis in Children. *Journal of Clinical Medicine*, **2019**, 8,	5.1	8
25	New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1561-1563	10.2	4
24	Isolated pulmonary interstitial glycogenosis associated with alveolar growth abnormalities: A long-term follow-up study. *Pediatric Pulmonology*, **2019**, 54, 837-846	3.5	7
23	Bi-allelic missense mutations in a patient with childhood ILD who reached adulthood. *ERJ Open Research*, **2019**, 5,	3.5	9
22	Genetic causes of surfactant protein abnormalities. *Current Opinion in Pediatrics*, **2019**, 31, 330-339	3.2	22

21	Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19. *Infection and Drug Resistance*, **2020**, 13, 3689-3694	4.2	6
20	A Case of Idiopathic Pulmonary Hemosiderosis in a 30-Year-Old Man. *Clinical Pulmonary Medicine*, **2020**, 27, 64-66	0.3	2
19	Interstitial lung diseases in children. *Presse Medicale*, **2020**, 49, 103909	2.2	14
18	Genetic Disorders of Surfactant Deficiency and Neonatal Lung Disease. *Current Respiratory Medicine Reviews*, **2020**, 15, 210-220	0.3	
17	Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: A registry-based case series. *Pediatric Pulmonology*, **2020**, 55, 909-917	3.5	8
16	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. *One Health*, **2020**, 9, 100131	7.6	15
15	Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. *Trials*, **2020**, 21, 307	2.8	3
14	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. *ERJ Open Research*, **2021**, 7,	3.5	1
13	Three Infants with Pathogenic Variants in the ABCA3 Gene: Presentation, Treatment, and Clinical Course. *Journal of Pediatrics*, **2021**, 231, 278-283.e2	3.6	1
12	Interstitial lung diseases in the neonatal period. **2021**, 213-230		0
11	Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease. *Cell Reports*, **2021**, 36, 109636	10.6	10
10	Acute Hydroxychloroquine Overdose: A Review of Published Pediatric Cases With Confirmed Hydroxychloroquine Exposure. *Pediatric Emergency Care*, **2021**,	1.4	
9	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. *Respiratory Investigation*, **2021**, 59, 709-740	3.4	2
8	Diffuse Parenchymal Lung Disease in Early Childhood. **2022**, 229-243		
7	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. *Anadolu Klinik Tıp Bilimleri Dergisi*, 204-215	0.3	0
6	Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. **2022**, 17,		0
5	Modern principles and prospects for drug therapy of interstitial lung diseases in children. **2022**, 67, 18-22		
4	Maladies interstitielles pulmonaires de l'enfant d'origine génétique. **2022**,		0

3	Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.	0
2	Childhood Interstitial Lung Disease.	0
1	Diagnostic workup of childhood interstitial lung disease. **2023**, 32, 220188	0